[go: up one dir, main page]

WO2018179374A1 - Composition cosmétique comprenant un surnageant de culture de fibroblastes dermiques et son procédé de fabrication - Google Patents

Composition cosmétique comprenant un surnageant de culture de fibroblastes dermiques et son procédé de fabrication Download PDF

Info

Publication number
WO2018179374A1
WO2018179374A1 PCT/JP2017/013714 JP2017013714W WO2018179374A1 WO 2018179374 A1 WO2018179374 A1 WO 2018179374A1 JP 2017013714 W JP2017013714 W JP 2017013714W WO 2018179374 A1 WO2018179374 A1 WO 2018179374A1
Authority
WO
WIPO (PCT)
Prior art keywords
culture supernatant
dermal fibroblasts
culture
cosmetic composition
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2017/013714
Other languages
English (en)
Japanese (ja)
Inventor
和典 古市
由載 小島
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cellbank Corp
Original Assignee
Cellbank Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellbank Corp filed Critical Cellbank Corp
Priority to PCT/JP2017/013714 priority Critical patent/WO2018179374A1/fr
Publication of WO2018179374A1 publication Critical patent/WO2018179374A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Definitions

  • the present invention relates to a cosmetic composition containing a culture supernatant of dermal fibroblasts and a method for producing the same.
  • the present invention also provides a cosmetic method comprising applying to the skin a composition containing a culture supernatant of dermal fibroblasts, use of the culture supernatant of dermal fibroblasts for the production of a cosmetic composition, And dermal fibroblast culture supernatant for use in cosmetic methods.
  • Skin regenerative medicine is known as one of regenerative medicine in the field of aesthetic medicine (Non-Patent Documents 1 to 6).
  • Skin regenerative medicine is a technique in which skin cells (dermal fibroblasts) isolated from a part of the patient's skin are cultured and the cultured cells are transplanted into the patient's skin.
  • Dermal fibroblasts are cells that form proteins that make up the skin, such as collagen, elastin, and hyaluronic acid, and are known to decrease with age.
  • the transplantation of dermal fibroblasts is effective for improving or improving the appearance and condition of the skin, such as reducing fine lines and improving elasticity.
  • the present invention provides a cosmetic composition containing a culture supernatant of dermal fibroblasts and a method for producing the same.
  • the present invention also provides a cosmetic method comprising applying to the skin a composition containing a culture supernatant of dermal fibroblasts, use of the culture supernatant of dermal fibroblasts for the production of a cosmetic composition, And a dermal fibroblast culture supernatant for use in cosmetic methods.
  • the inventor of the present case focused on the culture solution of dermal fibroblasts and started research. As a result of intensive studies, it has been found that a cosmetic composition having a high moisturizing effect and improving the state and appearance of the skin can be obtained by adding a culture supernatant of dermal fibroblasts to cosmetics. Based on this finding, the present invention has been completed.
  • the present invention may be as follows.
  • a cosmetic composition comprising a culture supernatant of dermal fibroblasts.
  • a method for producing a cosmetic composition comprising a culture supernatant of dermal fibroblasts, comprising the following steps: (I) culturing and passaging human-derived dermal fibroblasts; (Ii) recovering the culture supernatant of the culture obtained in (i); (Iii) concentrating the collected culture supernatant; (Iv) adding the culture supernatant concentrated in (iii) to the base cosmetic; Said method. [6] The method according to the above [5], comprising subculture at least twice in the step (i). [7] The above [5] or [6], wherein the last passage in step (i) comprises seeding at 0.6 to 1.5 ⁇ 10 6 cells per 40 mL of medium and culturing until confluent.
  • step (i) The culture in step (i) is performed using a serum-containing medium, wherein the serum is obtained from blood derived from the same subject as the subject from which dermal fibroblasts were collected [5] The method according to any one of [7] to [7]. [9] The method according to any one of [5] to [8] above, wherein step (iii) comprises concentrating the culture supernatant 1.5 to 30 times. [10] The above [5] to [9], wherein the step (iv) comprises adding the culture supernatant at 3% (w / w) to 10% (w / w) with respect to the weight of the base cosmetic. ] The method of any one of these.
  • human-derived dermal fibroblasts are transformed into the following steps: (A) Protease-treated skin pieces obtained from a human subject to separate the epidermis and dermis; (B) Shred dermis and culture in petri dish to spread dermal fibroblasts; The method according to any one of [5] to [10] above, which comprises
  • the present invention is useful in that it provides a new cosmetic composition having a high moisturizing effect and improving or improving the state and appearance of the skin.
  • Figure 1-1 shows a questionnaire survey of cosmetics containing concentrated skin cell-derived components (indicated as “with supernatant” in the graph) and cosmetics not containing the component (indicated as “without supernatant” in the graph) It is a graph which shows the result of having performed. Results are shown for dry skin, moisturizing feeling, fine lines, elasticity, sagging, brightness, spots, and rough skin.
  • FIG. 1-2 is a continuation of FIG. 1-1, and is a graph showing the results for pores, softness, texture, and glue.
  • FIG. 2-1 shows the metabolites (glucose (Glc), lactose (Lac), glutamine (Gln), ammonia (NH 3 ), glutamic acid (Glu) in the supernatant in the third subculture of dermal fibroblasts. It is a graph which shows the result of having evaluated increase / decrease of). The numbers in circles indicate the specimen numbers.
  • FIG. 2-2 shows the results of evaluating the increase / decrease of various ions (calcium ions (Ca), magnesium ions (Mg), sodium ions (Na)) in the supernatant in the third subculture of dermal fibroblasts. It is a graph to show. The numbers in circles indicate the specimen numbers.
  • FIG. 3 confirms that collagen is produced from dermal fibroblasts when dermal fibroblasts are cultured (cultured in 5% serum-containing HFDM-1 (+)) by the method shown in Examples 1 and 2. It is a graph.
  • the present application is a cosmetic composition comprising a culture supernatant of dermal fibroblasts.
  • the cosmetic composition is obtained by adding a dermal fibroblast culture supernatant to a base cosmetic.
  • the base cosmetic product is not particularly limited, and may be a lotion, a milky lotion (skin milk), a cream, a cosmetic liquid, a gel, a pack, or a mousse.
  • the composition of the base cosmetic is not particularly limited, and any component that is acceptable as a cosmetic may be included.
  • Ingredients preferably contained in the base cosmetic include, for example, Aspergillus / (Rice / Komenuka) fermentation broth, ascorbyl glucoside, ascorbyl palmitate 3Na, tripeptide-3, oligopeptide-6, caprooil tetrapeptide- 3, oligopeptide-34, hexapeptide-3, trifluoroacetyltripeptide-2, and the like.
  • the culture supernatant of dermal fibroblasts is a culture supernatant of a culture obtained by culturing human-derived dermal fibroblasts in a medium suitable for culturing human fibroblasts, or a concentrated solution thereof.
  • the medium is not particularly limited, and may be a medium having the characteristics described in the following ⁇ Method for producing cosmetic composition>, such as HFDM-1 (+) (Cell Science Research Institute). May be.
  • the medium is a serum-containing medium.
  • the culture supernatant of dermal fibroblasts is a culture supernatant of dermal fibroblasts isolated from a skin piece obtained from a subject using the obtained cosmetic composition or a concentrated solution thereof.
  • the serum-containing medium used for the culture may contain serum obtained from blood derived from the same subject as the subject.
  • the culture supernatant of dermal fibroblasts contained in the cosmetic composition of the present application is a concentrated culture supernatant.
  • the concentration rate of the culture supernatant is not particularly limited, but may be 1.5 to 30 times, 2 to 20 times, 2 to 15 times, 5 to 15 times, 5 to 10 times.
  • the amount of the dermal fibroblast culture supernatant or concentrated solution contained in the cosmetic composition of the present application is not particularly limited. For example, 2 to 15% (w / w), 3 to It may be 10% (w / w), 3-7% (w / w), 3-5% (w / w).
  • the dermal fibroblast culture supernatant includes the following: arginine hydrochloride, aspartic acid, cysteine hydrochloride, glutamic acid, glutamine, glycine, histidine hydrochloride, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine , Tryptophan, tyrosine, valine, biotin, choline chloride, folic acid, niacinamide, riboflavin, thiamine hydrochloride, tocopherol, arachidonic acid, cholesterol, linoleic acid, linolenic acid, myristic acid, oleic acid, palmitic acid, stearic acid, thymidine, One or more components selected from the group consisting of glucose, sodium pyruvate, succinic acid, and recombinant human EFG may be included.
  • the cosmetic composition of the present application may be produced by the method described in “Method for producing cosmetic composition” below.
  • the present application is a method for producing a cosmetic composition comprising a culture supernatant of dermal fibroblasts, the following steps: (I) culturing and passaging human-derived dermal fibroblasts; (Ii) recovering the culture supernatant of the culture obtained in (i); (Iii) concentrating the collected culture supernatant; (Iv) adding the culture supernatant concentrated in (iii) to the base cosmetic; The method.
  • human-derived dermal fibroblasts dermal fibroblasts isolated from skin pieces collected from human subjects may be used as they are, or cryopreserved dermal fibroblasts may be used.
  • the following steps (A) Protease-treated skin pieces obtained from a human subject to separate the epidermis and dermis; (B) Shred dermis and culture in petri dish to spread dermal fibroblasts; Thus, dermal fibroblasts can be obtained.
  • the protease used in the step (a) is not particularly limited as long as it is a protease capable of separating the epidermis and the dermis.
  • the extension of the dermal fibroblasts in the step (b) is performed by culturing the minced dermis in a medium suitable for culturing human fibroblasts.
  • a medium suitable for culturing human fibroblasts for example, those described below as those used in step (i) can be used.
  • cryopreserved dermal fibroblasts When using cryopreserved dermal fibroblasts, the frozen cells can be thawed and used by methods known to those skilled in the art. For example, dermal fibroblasts cryopreserved by rapid thawing with a heat block can be thawed and used.
  • the cryopreserved dermal fibroblasts may be obtained by cryopreserving a part of the dermal fibroblasts cultured in the above step (i). At that time, the number of passages of the dermal fibroblasts to be cryopreserved is not particularly limited as long as it has been subcultured at least once.
  • cryopreservation of dermal fibroblasts can be performed using any method known to those skilled in the art, for example, it may be performed by the method described in step (3-2) of Example 1 .
  • dermal fibroblasts may be cultured by any method known to those skilled in the art.
  • the medium is not particularly limited as long as it is a medium suitable for culturing human fibroblasts.
  • Suitable media for culturing human fibroblasts include the following components: One or more components selected from the group consisting of arginine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, tryptophan, and threonine as amino acids;
  • a medium suitable for culturing human fibroblasts further comprises the following components: One or more components selected from the group consisting of arachidonic acid, cholesterol, linoleic acid, linolenic acid, myristic acid, oleic acid, palmitic acid, and stearic acid as lipids; and / or as a protein, recombinant human EGF and / or recombinant human insulin; May be included.
  • a medium for example, HFDM-1 (+) (Cell Science Laboratory Co., Ltd.) can be used.
  • the medium is a serum-containing medium.
  • the type of serum contained in the serum-containing medium is not particularly limited, but may preferably be obtained from blood derived from the same subject as the subject from which the dermal fibroblasts to be cultured are collected.
  • the amount of serum contained in the medium is not particularly limited. For example, 0.5 to 20% (v / v), 1 to 15% (v / v), 3% to 15% (v / v), It may be 5% to 10% (v / v).
  • the culture may be performed, for example, in a CO 2 incubator at 37 ° C.
  • the culture may be performed by plate culture or suspension culture. Preferably it is performed by plate culture.
  • the number of passages of dermal fibroblasts is not particularly limited, but is preferably performed at least twice or at least three times. Since subculture is performed for the purpose of expanding the culture scale and removing impurities, there is no upper limit to the number of times. However, in view of the fact that the production cost of the cosmetic composition increases as the number of passages increases, the upper limit of the number of passages may be 5, 7, or 10.
  • the passage number is the passage number for the culture after thawing of the cells.
  • the culture scale in step (i) is not particularly limited, but preferably the final passage may include seeding at 0.6 to 1.5 ⁇ 10 6 cells per 40 mL of medium and culturing until confluent. Good. When 0.6-1.5 ⁇ 10 6 cells are seeded and cultured in 40 mL of medium in a 225 cm 2 flask, they reach confluence in about 4 days of culture.
  • step (ii) the culture supernatant of the culture obtained in step (i) is collected, and the culture obtained in step (i) is the last passage of step (i).
  • the culture supernatant can be collected by any method known to those skilled in the art. In the case of plate culture, the culture supernatant may be collected by aspiration with a pipette. In the case of suspension culture, the culture supernatant may be collected by decanting the culture supernatant after centrifugation of the culture solution.
  • Concentration of the culture supernatant in step (iii) can be performed by any method known to those skilled in the art.
  • the culture supernatant can be concentrated by centrifuging the culture supernatant in a tube with an ultrafiltration membrane.
  • the concentration rate of the culture supernatant is not particularly limited, but may be 1.5 to 30 times, 2 to 20 times, 2 to 15 times, 5 to 15 times, 5 to 10 times.
  • step (iv) the concentrated culture supernatant obtained in step (iii) is added to the base cosmetic. After the concentrated culture supernatant is added to the base cosmetic, it is mixed to be uniform.
  • the base cosmetic is as described above in the item of the cosmetic composition.
  • the concentrated culture supernatant is 2-15% (w / w), 3-10% (w / w), 3-7% (w / w) 3-5% (w / W).
  • the present application provides a cosmetic method comprising applying to a subject's skin a composition comprising a culture supernatant of dermal fibroblasts.
  • the composition containing the culture supernatant of dermal fibroblasts may be the above-described cosmetic composition of the present application.
  • the composition is applied to the skin once a day or twice a day.
  • the period of using the composition is not particularly limited, but is preferably 7 days or longer, 14 days or longer, 1 month or longer. There is no upper limit for the period of use.
  • the cosmetic method of the present application is a method for improving or improving the state and appearance of the skin.
  • improvement or improvement of skin condition and appearance means improvement of skin dryness, improvement of moisturizing feeling of skin, improvement of fine lines (reduction), improvement of elasticity, improvement of sagging (reduction), skin brightness
  • One or more states selected from the group consisting of: improvement of skin, improvement of spots (less noticeable), improvement of rough skin, improvement of pores (less noticeable), improvement of softness, improvement of texture, and improvement of makeup Means improvement or improvement.
  • the present application provides the use of a dermal fibroblast culture supernatant for the manufacture of a cosmetic composition.
  • the present application provides a culture supernatant of dermal fibroblasts for use in a cosmetic method.
  • the definitions of the terms “beauty method” and “culture supernatant of dermal fibroblasts” are as described above.
  • Example 1 Production of Cosmetic Composition (1) / Production from Skin Piece A cosmetic composition was produced by the following procedures (1) to (7).
  • step (1-1) Finely slicing the skin piece
  • the centrifuge tube is turned over so that the lid is on the bottom, the skin piece is attached to the inside of the lid, Returned to the direction.
  • the epidermis and dermis were separated on the lid using two sterilized tweezers.
  • the skin pieces were returned to the Dispase (registered trademark) I solution, reacted at 37 ° C. for another 10 minutes, and then separated.
  • the dermis was transferred to a 50 mL centrifuge tube containing 20 mL physiological saline and stirred vigorously for 15 seconds in physiological saline.
  • a 10-cm culture dish was dispensed with 10 mL of 10% human serum medium per dish, and the bottom surface was covered with the medium, and then about 8 mL was sucked back into the pipette and transferred to a new centrifuge tube.
  • the dermis was transferred to the above culture dish, and was cut into approximately 1 mm squares on the culture dish prepared in (iii). When lifting the skin piece is large, and while standing in a CO 2 incubator at 37 ° C.. The medium transferred to the new centrifuge tube in (iii) was returned to the culture dish to make the total volume 10 mL.
  • the treatment time was extended if observation of the cells with a microscope was not observed, and the start of cell detachment was not observed.
  • the cell / Tryple Select suspension in the dish was aspirated with a pipette and dropped onto the dish surface to detach as many cells as possible.
  • the cell suspension was collected in the centrifuge tube of step (i). 4 mL of HFDM was added to the dish after cell recovery and washed together, and recovered in the centrifuge tube. The cell suspension was centrifuged for 6 minutes at 4 ° C. and 330 ⁇ g (1300 rpm).
  • HFDM was added to the cell suspension to adjust the number of cells per mL to be 0.6 to 1.5 ⁇ 10 6 cells or more.
  • Vi 37 mL of HFDM and 2 mL of serum were added to a 225 cm 2 flask. Inoculate 1 mL of cell suspension into the flask. The flask seeded with the cells was placed in a 37 ° C. CO 2 incubator and cultured until the cell density in the flask reached a nearly saturated state (about 4 days).
  • step (i) The cell / Triple Select suspension was collected in the centrifuge tube of step (i). 10 mL of HFDM was added to the flask after cell recovery, and the cells were washed together so as to remove cells adhering to the flask and recovered in the centrifuge tube.
  • Step (5) The tube with an ultrafiltration membrane was washed in the same manner as in (i).
  • (i) was added to the top of the washed tube and centrifuged at 4 ° C. and 3000 ⁇ g.
  • a 10-fold concentration ratio was obtained by centrifuging for 3 hours, but the centrifugation time was appropriately adjusted so as to obtain a desired concentration ratio.
  • concentration by 10-fold concentration once the concentration is 10-fold, the new ultrafiltration membrane tube is collected so that it is within 20 mL, and centrifuged until the desired concentration ratio is reached.
  • Step of adding concentrated skin cell-derived component to base cosmetic (5) or (6) The concentrated liquid obtained in (6) is added to base cosmetic ( skin lotion, milky lotion, cream) to make a cosmetic composition Obtained.
  • the concentrated solution was added so as to have a ratio of 3 to 10% regardless of whether the base cosmetic was skin lotion, milky lotion, or cream.
  • Example 2 Production of cosmetic composition (2) / Production from storage cells (P) A cosmetic composition was produced by the following procedures (1) to (7).
  • Example 1 (1) Thawing of cells Thaw the stored cells (P) in Example 1, step (3-2).
  • the number of cryotubes ⁇ 9 mL of HFDM was placed in a centrifuge tube.
  • Ii A frozen cryotube containing P2 storage cells was rapidly thawed in a 37 ° C. heat block. The thawed cell suspension was aspirated, the tip of the pipette was placed on the liquid surface of the centrifuge tube of (i) above, the cell suspension was poured, and pipetting was performed to obtain a cell suspension. 1 mL of the cell suspension was aspirated with the same pipette, and the cryotube after cell collection was pipetted several times to wash together, and the cells were collected in a centrifuge tube.
  • (Iii) HFDM was added to the cell suspension obtained in the above step (1-1) (iii), and the number of cells per mL was adjusted to the number of seeded cells. 1 mL of the cell suspension was seeded in each flask. Each tumor flask was placed in a 37 ° C. CO 2 incubator and cultured until the cell density in the flask was nearly saturated (4-6 days).
  • Example 3 Targeting 31 monitors from the cosmetics open call for cosmetics, each monitor is the closest to a cosmetic composition (skin lotion, milky lotion, and cream) containing or not containing concentrated skin cell-derived components.
  • a questionnaire survey was conducted on the comparison with the cosmetics used.
  • a cosmetic composition containing a concentrated skin cell-derived component a cosmetic composition containing 5% (w / w) of a double concentrate of the culture supernatant of dermal fibroblasts was used.
  • each monitor used the cosmetic composition to be evaluated continuously for 2 weeks. Of the 31 patients, 16 evaluated the feeling of use for cosmetics not containing concentrated skin cell-derived ingredients, and 15 evaluated the feeling of use for cosmetics containing the ingredients.
  • Each group was randomly divided, and each monitor did not disclose whether the cosmetic product being evaluated contained a concentrated skin cell-derived component.
  • Cosmetic compositions containing concentrated skin cell-derived components were often evaluated as improved, particularly in terms of skin dryness and moisturizing feeling. The evaluation that the effect on rough skin, dullness, and pores was realized was more in the case of cosmetic compositions containing concentrated skin cell-derived components. In addition, there were more evaluations of cosmetic compositions containing concentrated skin cell-derived components that were comprehensively recommended to others.
  • Example 4 Evaluation of culture supernatant (1)-Metabolite and various ions
  • dermal fibroblasts were cultured in the same manner as in Example 1 or 2, and the third round of step (4) Subculture was performed for 5 days.
  • the culture solution is sampled every day, and metabolites (glucose (Glc), lactose (Lac), glutamine (Gln), ammonia (NH 3 ), glutamic acid (Glu)) and various ions (calcium ions) in the culture supernatant.
  • Changes in (Ca), magnesium ions (Mg), and sodium ions (Na) were evaluated using Cedex Bio (Roche Diagnostics).
  • a medium not seeded with dermal fibroblasts was used as a control.
  • the amount of various metabolites and ions was also evaluated in the same manner for the double concentrate of the culture supernatant after 5 days of culture.
  • Glucose and glutamic acid tended to decrease with the passage of the culture days. Lactose, glutamic acid, and ammonia tended to increase with the passage of the culture days. There was no change in the amount of various ions before and after the culture. It was also confirmed that the metabolite and various ion components contained in the culture supernatant were not lost even when the culture supernatant was concentrated.
  • Example 4 Evaluation of Culture Supernatant (2) Collagen Production
  • dermal fibroblasts were cultured in HFDM-1 (+) medium containing 5% serum, and 3 in step (4).
  • the first subculture was performed.
  • the same subculture was performed in a 10% serum-containing MEM ⁇ medium.
  • the amount of collagen contained in the supernatant of the third subculture was evaluated.
  • the HFDM-1 (+) medium is a medium suitable for fibroblast culture
  • the MEM ⁇ medium is a medium widely used for culturing mammalian cells.
  • the former includes a protein or lipid component such as recombinant human EGF or recombinant human insulin.
  • the cosmetic composition containing the culture supernatant of dermal fibroblasts of the present invention provides a new cosmetic composition that has a high moisturizing effect and improves the state and appearance of the skin.
  • tailor-made cosmetics that use dermal fibroblast culture supernatant obtained from the subject's own skin will open up new markets to meet consumer needs for cosmetics that match their skin quality. Is.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention concerne une composition cosmétique comprenant un surnageant de culture de fibroblastes dermiques et son procédé de fabrication. La présente invention concerne également : une méthode de soins de beauté comprenant l'application sur la peau d'une composition, ladite composition comprenant un surnageant de culture de fibroblastes dermiques ; l'utilisation d'un surnageant de culture de fibroblastes dermiques permettant la fabrication d'une composition cosmétique ; et un surnageant de culture de fibroblastes dermiques destiné à être utilisé dans une méthode de soins de beauté.
PCT/JP2017/013714 2017-03-31 2017-03-31 Composition cosmétique comprenant un surnageant de culture de fibroblastes dermiques et son procédé de fabrication Ceased WO2018179374A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/JP2017/013714 WO2018179374A1 (fr) 2017-03-31 2017-03-31 Composition cosmétique comprenant un surnageant de culture de fibroblastes dermiques et son procédé de fabrication

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2017/013714 WO2018179374A1 (fr) 2017-03-31 2017-03-31 Composition cosmétique comprenant un surnageant de culture de fibroblastes dermiques et son procédé de fabrication

Publications (1)

Publication Number Publication Date
WO2018179374A1 true WO2018179374A1 (fr) 2018-10-04

Family

ID=63674878

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2017/013714 Ceased WO2018179374A1 (fr) 2017-03-31 2017-03-31 Composition cosmétique comprenant un surnageant de culture de fibroblastes dermiques et son procédé de fabrication

Country Status (1)

Country Link
WO (1) WO2018179374A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115947790A (zh) * 2022-11-15 2023-04-11 诺赛联合(北京)生物医学科技有限公司 成纤维细胞外基质制备的三型胶原蛋白组合物

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63185918A (ja) * 1986-12-23 1988-08-01 ユニリーバー・ナームローゼ・ベンノートシヤープ 化粧用組成物
JPH05501108A (ja) * 1989-08-17 1993-03-04 エルブィエムアー　リシェルシェ 皮膚色素形成コレウス抽出物含有組成物
JP2006131600A (ja) * 2004-11-09 2006-05-25 R & D Cell-Science Optional Medico:Kk 発毛促進のためのヒト細胞組成物
JP2009519971A (ja) * 2005-12-14 2009-05-21 オルガノジェネシス インク． スキンケア組成物及び治療法
JP2012504598A (ja) * 2008-10-05 2012-02-23 フリードランダー，ヒミエ 皮膚細胞の成長を促す方法、皮膚の状態又は頭髪の状態を治療する組成物
JP2013505011A (ja) * 2009-09-18 2013-02-14 フジフィルム・ダイオシンス・バイオテクノロジーズ ・ユーケイ・リミテッド 幹細胞馴化培地組成物

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63185918A (ja) * 1986-12-23 1988-08-01 ユニリーバー・ナームローゼ・ベンノートシヤープ 化粧用組成物
JPH05501108A (ja) * 1989-08-17 1993-03-04 エルブィエムアー　リシェルシェ 皮膚色素形成コレウス抽出物含有組成物
JP2006131600A (ja) * 2004-11-09 2006-05-25 R & D Cell-Science Optional Medico:Kk 発毛促進のためのヒト細胞組成物
JP2009519971A (ja) * 2005-12-14 2009-05-21 オルガノジェネシス インク． スキンケア組成物及び治療法
JP2012504598A (ja) * 2008-10-05 2012-02-23 フリードランダー，ヒミエ 皮膚細胞の成長を促す方法、皮膚の状態又は頭髪の状態を治療する組成物
JP2013505011A (ja) * 2009-09-18 2013-02-14 フジフィルム・ダイオシンス・バイオテクノロジーズ ・ユーケイ・リミテッド 幹細胞馴化培地組成物

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115947790A (zh) * 2022-11-15 2023-04-11 诺赛联合(北京)生物医学科技有限公司 成纤维细胞外基质制备的三型胶原蛋白组合物
WO2024104351A1 (fr) * 2022-11-15 2024-05-23 诺赛联合(北京)生物医学科技有限公司 Composition de collagène de type iii préparée à partir d'une matrice extracellulaire de fibroblastes

Similar Documents

Publication Publication Date Title
AU2010244047B2 (en) Methods and apparatuses for isolating and preparing stem cells
Kraus et al. Co-culture of human adipose-derived stem cells with tenocytes increases proliferation and induces differentiation into a tenogenic lineage
EP2368974A1 (fr) Procédés d'extraction de cellules souches interstitielles d'embryon humain ou animal, et d'extraction de leur sécrétion
TW200902718A (en) Procurement, isolation, and cryopreservation of endometrial/menstrual cells
JPWO2005063967A1 (ja) 哺乳動物の骨髄細胞または臍帯血由来細胞と脂肪組織を利用した心筋細胞の誘導
KR20120008223A (ko) 양막유래 중간엽 줄기세포 배양을 위한 배지조성물 및 이를 이용한 양막유래 중간엽 줄기세포의 배양방법
CN105267243B (zh) 一种消除皮肤妊娠纹的干细胞提取物
CN104087551B (zh) 一种体外分离培养人的表皮细胞的方法
CN113564111B (zh) 一种低氧培养脐带来源间充质干细胞的方法
EP1071747B1 (fr) Lignee de cellules immortalisees derivees de tissus cutanes humains normaux
KR101349183B1 (ko) 3차원 세포배양으로 수득한 조건 배지를 유효성분으로 포함하는 허혈성 질환 치료용 약학적 조성물
CN104762257A (zh) 一种从脐带制备间充质干细胞的方法
CN109943526B (zh) 一种促间充质干细胞增殖的无血清多肽组合物
CN109628388B (zh) 用消化酶组合物从胎盘血管分离间充质干细胞
Fink et al. Isolation and expansion of adipose-derived stem cells for tissue engineering
JP2020063192A (ja) 真皮線維芽細胞の培養上清液を含む化粧用組成物およびその製造方法
Lee et al. Minimal cube explant provides optimal isolation condition of mesenchymal stem cells from umbilical cord
CN111849883A (zh) 一种用于体外扩增自体人毛囊间充质干细胞培养基及其培养方法
Call et al. Hair follicle stem cell isolation and expansion
Mattei et al. Validated methods for isolation and qualification of mesenchymal stromal/stem cells from different sources
WO2018179374A1 (fr) Composition cosmétique comprenant un surnageant de culture de fibroblastes dermiques et son procédé de fabrication
RU2012107674A (ru) Биотрансплантат для восстановления объема костной ткани при дегенеративных заболеваниях и травматических повреждениях костей и способ его получения
WO2013117618A1 (fr) Processus pour évaluer un agent actif ou des agents actifs capables de préserver la fonctionnalité de cellules souches épithéliales
CN1872025A (zh) 一种美容护肤产品、其制备方法
CN116396925A (zh) 一种毛囊干细胞的增殖方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17903431

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17903431

Country of ref document: EP

Kind code of ref document: A1